Bohai Pharmaceuticals Group's Cash & cash equivalent grew by 37.8 % in the Q1 2014 sequentially, faster than Current Liabilities, this led to improvement in Bohai Pharmaceuticals Group's Quick Ratio to 1.02 a new company high.

Within Biotechnology & Pharmaceuticals industry 107 other companies have achieved higher Quick Ratio than Bohai Pharmaceuticals Group in first quarter 2014. While Quick Ratio total ranking has improved so far during the Q1 2014 to 2107, from total ranking in the fourth quarter 2014 at 2148.

Explain Quick Ratio?
How much Cash & cash equivalents BOPH�s has?
What are BOPH�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

BOPH Quick Ratio	(Sep 30 2014) Q1	(Jun 30 2014) Q4	(Mar 31 2014) Q3	(Dec 31 2013) Q2	(Sep 30 2013) Q1
Y / Y Current Liabilities Change	-5.33 %	-10.41 %	-1.84 %	3.72 %	78.02 %
Y / Y Cash & cash equivalent Change	82.77 %	84.06 %	95.54 %	65.24 %	-5.64 %
Quick Ratio MRQ	1.02	0.91	0.71	0.46	0.53
BOPH's Total Ranking	# 2107	# 2148	# 2149	# 1809	# 1809
Seq. Current Liabilities Change	23.19 %	17.55 %	-18.22 %	-20.07 %	16.58 %
Seq. Cash & cash equivalent Change	37.8 %	50.5 %	24.97 %	-29.48 %	38.77 %

Quick Ratio first quarter 2014 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 108
Healthcare Sector	# 528
Overall Market	# 2107

Quick Ratio Statistics
High	Average	Low
1.02	0.65	0.29
(Sep 30 2014)		(Dec 31 2012)

Financial Statements
Bohai Pharmaceuticals Group's Current Liabilities	$ 49 Millions	Visit BOPH's Balance sheet
Bohai Pharmaceuticals Group's Cash & cash equivalent	$ 50 Millions	Visit BOPH's Balance sheet
Source of BOPH's Sales		Visit BOPH's Sales by Geography

Cumulative Bohai Pharmaceuticals Group's Quick Ratio

BOPH's Quick Ratio for the trailling 12 Months

BOPH Quick Ratio	(Sep 30 2014) 12 Months	(Jun 30 2014) 12 Months	(Mar 31 2014) 12 Months	(Dec 31 2013) 12 Months	(Sep 30 2013) 12 Months
Y / Y Current Liabilities TTM Growth	-3.83 %	12.79 %	27.87 %	22.8 %	24.44 %
Y / Y Cash & cash equivalent TTM Growth	82.46 %	47.22 %	11.55 %	-14.82 %	-30.14 %
Quick Ratio TTM	0.79	0.64	0.53	0.46	0.41
Total Ranking TTM	# 3385	# 1309	# 3277	# 3266	# 3476
Seq. Current Liabilities TTM Growth	-1.65 %	-2.7 %	-0.37 %	0.87 %	15.34 %
Seq. Cash & cash equivalent TTM Growth	21.15 %	18.32 %	14.97 %	10.72 %	-2.25 %

Quick ratio ranking by company, industry and sector >> Back to BOPH Financial Strength Comparisons >> Go to Compare BOPH Quick Ratio to its Competitors

On the trailing twelve months basis BOPH Cash & cash equivalent soared by 82.77 % in Q1 2014 year on year, while Current Liabilities grew to $49 millions, this led to increase in in Bohai Pharmaceuticals Group's Quick Ratio to 0.79, above BOPH average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 50 other companies have achieved higher Quick Ratio than Bohai Pharmaceuticals Group. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2014 from 1309 to 3385.

Explain Quick Ratio?
How much Cash & cash equivalents BOPH�s has?
What are BOPH�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 51
Healthcare Sector	# 398
Within the Market	# 3385

trailing twelve months Quick Ratio Statistics
High	Average	Low
0.79	0.58	0.41
(Sep 30 2014)		(Sep 30 2013)

Companies with similar Quick Ratio in the quarter ending Sep 30 2014, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Sep 30 2014 MRQ Cash & cash equivalent	Sep 30 2014 MRQ Current Liabilities
Biocryst Pharmaceuticals Inc	2.55	$ 127.284 Millions	$ 49.823 Millions
Protalix Biotherapeutics inc	2.47	$ 60.317 Millions	$ 24.384 Millions
Eloxx Pharmaceuticals Inc	2.27	$ 3.837 Millions	$ 1.687 Millions
Coherus Oncology inc	2.20	$ 100.925 Millions	$ 45.781 Millions
Cellular Biomedicine Group Inc	2.01	$ 9.816 Millions	$ 4.895 Millions
China Biologic Products Holdings Inc	1.77	$ 139.984 Millions	$ 79.090 Millions
Dendreon Corp	1.68	$ 106.861 Millions	$ 63.524 Millions
Moderna Inc	1.40	$ 3.203 Millions	$ 2.280 Millions
Qiagen N v	1.34	$ 576.703 Millions	$ 431.626 Millions
Lineage Cell Therapeutics Inc	1.27	$ 7.416 Millions	$ 5.831 Millions
Polarityte Inc	1.22	$ 7.196 Millions	$ 5.905 Millions
Exelixis Inc	1.17	$ 204.212 Millions	$ 173.912 Millions
Gilead Sciences Inc	1.04	$ 6,316.326 Millions	$ 6,054.952 Millions
Bohai Pharmaceuticals Group, Inc.	1.02	$ 49.514 Millions	$ 48.767 Millions
Titan Pharmaceuticals Inc	1.00	$ 7.450 Millions	$ 7.461 Millions
Biogen Inc	0.96	$ 1,861.346 Millions	$ 1,940.647 Millions
Premier Biomedical Inc	0.88	$ 0.047 Millions	$ 0.053 Millions
Xtant Medical Holdings Inc	0.74	$ 6.953 Millions	$ 9.376 Millions
Enzo Biochem Inc	0.68	$ 16.591 Millions	$ 24.509 Millions
Adaptive Biotechnologies Corporation	0.59	$ 20.103 Millions	$ 34.306 Millions
Beam Therapeutics Inc	0.31	$ 0.401 Millions	$ 1.297 Millions
Fennec Pharmaceuticals Inc	0.28	$ 1.092 Millions	$ 3.901 Millions

Date modified: 2026-09-12T06:21:53+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.